Product Description
Mechanisms of Action: VEGF Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Belgium | Croatia | Czech | Denmark | Estonia | European Medicines Agency | Finland | Germany | Greece | Hungary | Iceland | Ireland | Italy | Latvia | Lithuania | Netherlands | New Zealand | Norway | Poland | Portugal | Romania | Slovakia | Spain | Sweden | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: AVEO
Company Location: BOSTON MA 02108
Company CEO: Michael Bailey
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Belgium, Brazil, Canada, Chile, Czech Republic, France, Germany, Italy, Mexico, Poland, Portugal, Spain, United Kingdom, United States
Active Clinical Trial Count: 5
Highest Development Phases
Phase 3: Renal Cell Carcinoma
Phase 2: Adenocarcinoma|Bile Duct Cancer|Breast Cancer|Cholangiocarcinoma|Gallbladder Cancer|Neuroendocrine Carcinoma|Neuroendocrine Tumors|Ovarian Cancer|Pancreatic Cancer|Prostate Cancer|Sarcoma|Soft Tissue Cancer|Vulvar Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCI-2023-07385 | P2 |
Recruiting |
Renal Cell Carcinoma |
2026-11-01 |
12% |
| 2021-000050-26 | P3 |
Active, not recruiting |
Renal Cell Carcinoma |
2025-09-30 |
|
| AV-951-20-304 | P3 |
Active, not recruiting |
Renal Cell Carcinoma |
2025-07-31 |
|
| UF-STO-ETG-003 | P2 |
Recruiting |
Neuroendocrine Carcinoma|Ovarian Cancer|Sarcoma|Gallbladder Cancer|Adenocarcinoma|Bile Duct Cancer|Neuroendocrine Tumors|Vulvar Cancer|Pancreatic Cancer|Soft Tissue Cancer|Prostate Cancer|Cholangiocarcinoma|Breast Cancer |
2025-06-01 |
12% |
| TiNivo-2 | P3 |
Active, not recruiting |
Renal Cell Carcinoma |
2024-04-01 |
35% |